T1	Participants 112 158	patients with untreated acute myeloid leukemia
T2	Participants 0 19	Long-term follow-up
T3	Participants 414 555	In 1996, survival data were updated from three prospective, randomized comparisons of idarubicin and daunorubicin that began in 1984 and 1985
T4	Participants 557 638	These were trials of the Memorial Sloan-Kettering Cancer Center (MSKCC), the U.S.
T5	Participants 639 710	Multicenter Study Group, and the Southeastern Cancer Study Group (SEG).
T6	Participants 711 778	The original results of these trials were reported in 1991 and 1992
